Effects of nicorandil on monocrotaline-induced pulmonary arterial hypertension in rats

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 4, 2005, Pages 452-458

  Hongo, Minoru ^a   Mawatari, Eiichiro ^b   Sakai, Akio ^b   Ruan, Zonghai ^b   Koizumi, Tomonobu ^b   Terasawa, Fumiko ^a   Yazaki, Yoshikazu ^b   Kinoshita, Osamu ^b   Ikeda, Uichi ^b   Shibamoto, Toshishige ^c  

^a SHINSHU UNIVERSITY   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Nicorandil; Nitric oxide; Pulmonary arterial hypertension

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; MONOCROTALINE; NICORANDIL; PADGEM PROTEIN; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; ENDOTHELIUM CELL; LUNG BLOOD VESSEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIGENS, CD45; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOTTING, WESTERN; ENDOTHELIUM, VASCULAR; FOLLOW-UP STUDIES; HEART RATE; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; MALE; MONOCROTALINE; NICORANDIL; NITRIC OXIDE SYNTHASE; P-SELECTIN; PROLIFERATING CELL NUCLEAR ANTIGEN; PULMONARY ARTERY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; VASODILATOR AGENTS;

EID: 26044480636     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000176728.74690.09     Document Type: Article

References (38)

1. Farber HW, Loscalzo JL. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655-1665.
2. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004;25:2243-2278.
3. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214-221.
4. Tuder RM, Cool CD, Gearci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925-1932.
5. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
6. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998;338:273-277.
7. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119-1123.
8. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan in patients with pulmonary artery hypertension: a randomized, placebo controlled, multicenter study. N Engl J Med. 2002;346:896-903.
9. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-1436.
10. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis. 2002;45:173-202.
11. Hoeper MM, Galie N, Simonneau G, et al. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165:1209-1216.
12. Tuder RM, Zaiman AL. Prostacyclin analogs as the brakes for pulmonary artery smooth muscle cell proliferation: Is it sufficient to treat severe pulmonary hypertension? Am J Respir Cell Mol Biol. 2002;26:171-174.
13. Galic N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis. 2002;45:213-224.
14. Sharma S. Treatment of pulmonary arterial hypertension: a step forward. Chest. 2003;124:8-10.
15. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109:159-165.
16. Humbert M, Morreli NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:13S-24S.
17. Hongo M, Takenaka H, Uchikawa S, et al. Coronary microvascular response to intracoronary administration of nicorandil. Am J Cardiol. 1995;75:246-250.
18. Akai K, Wang Y, Sato K, et al. Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 1995;26:541-547.
19. ATP channel in unstable angina: Is this a clinical manifestation of myocardial preconditioning? Eur Heart J. 1999;20:51-57.
20. Sato T, Sasaki N, O'Rourke B, et al. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. J Am Coll Cardiol. 2000;35:514-518.
21. Horinaka S, Kobayashi N, Higashi T, et al. Nicorandil enhances cardiac endothelial nitric oxide synthase expression via activation of adenosine triphosphate-sensitive K channel in rat. J Cardiovasc Pharmacol. 2001;38:200-210.
22. Sanada H, Node K, Asanuma H, et al. Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis. J Am Coll Cardiol. 2002;40:991-997.
23. Hironaka E, Hongo M, Sakai A, et al. Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res. 2003;60:692-699.
24. Hongo M, Ryoke T, Schoenfeld J, et al. Effects of growth hormone on cardiac dysfunction and gene expression in genetic murine dilated cardiomyopathy. Basic Res Cardiol. 2000;95:431-441.
25. Cowan KN, Heilbut A, Humpl T, et al. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med. 2000;6:698-702.
26. Doring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol. 1992;20(Suppl 3):S74-S81.
27. Di Somma S, Liguori V, Verdecchia P, et al. A double-blind comparison of nicorandil and metoprolol in patients with effort stable angina. Cardiovasc Drugs Ther. 1993;7:119-123.
28. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol. 1989;63:18J-24J.
29. The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomized trial. Lancet. 2002;359:1269-1275.
30. Horinaka S, Kobayashi N, Yabe A, et al. Nicorandil protects against lethal ischemic ventricular arrhythmias and up-regulates endothelial nitric oxide synthase expression and sulfonylurea receptor 2 mRNA in conscious rats with acute myocardial infarction. Cardiovasc Drugs Ther. 2004;18:13-22.
31. Fishman AP, Fishman MC, Freeman BA, et al. Mechanisms of proliferative and obliterative vascular diseases: insights from the pulmonary and systemic circulations. NHLBI Workshop Summary. Am J Respir Crit Care Med. 1998;158:670-674.
32. Yi ES, Kim H, Ahn H, et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension: a morphometric and immunohistochemical study. Am J Respir Crit Care Med. 2000;162:1577-1586.
33. Wilson DW, Segall HJ, Pan LC, et al. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol. 1992;22:307-325.
34. Lame MW, Jones AD, Wilson DW, et al. Protein targets of monocrotaline pyrrole in pulmonary artery endothelial cells. J Biol Chem. 2000;275:29091- 29099.
35. Ghofrani HA, Pepke-Zaba J, Barbera JA, et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:68S-72S.
36. Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation. 2003;108:1640-1645.
37. Abe K, Shimokawa H, Morikawa K, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res. 2004;94:385-393.
38. Rakhit RD, Marber MS. Nitric oxide: an emerging role in cardioprotection? Heart. 2001;86:368-372.